The Evidence Layer for Scientific AI

 Quick Explanation Copied

 Long Explanation

1. Prescribe a High Physical Activity Dose — The Evidence

In a randomized trial of 202 overweight adults, participants prescribed a high activity goal (2500 kcal/week) maintained ~2249 kcal/week expenditure and lost 6.7 kg at 12 months, versus 4.1 kg in the standard-therapy group prescribed ~1000 kcal/week — a durable advantage across 18 months of follow-up (High vs standard PA goal RCT). Consensus reviews converge on a dose–response: 150–250 min/week moderate activity prevents weight gain; 250–300 min/week enables clinically significant weight loss (ACSM dose thresholds). Diet plus higher activity outperforms either alone for long-term maintenance (PA dose review). Resistance training adds muscular strength but does not substitute for aerobic dose (Resistance training role). Note: activity data are largely self-reported, and injury rates can undermine adherence.

2. Target ~5–10% Weight Loss for Organ-Level Metabolic Benefit

For fatty liver disease (the hepatic face of metabolic dysfunction), the ILTS consensus specifies graded thresholds: ≥5% weight loss improves liver histology, >7% reduces inflammation, >10% can improve fibrosis; a Mediterranean-style diet (~450 kcal/day deficit), restricting industrial fructose to <5% of carbohydrate intake, and both aerobic and resistance exercise form the foundation (ILTS NASH lifestyle thresholds). The same 5–10% target is recommended preconception for obese women to reduce preeclampsia, cesarean, and neonatal risks (Preconception 5–10% target).

3. Protect Bone and Muscle While Losing Weight

Weight loss is not universally benign. In an 18-month RCT of 236 premenopausal women (44–50 y), lifestyle weight loss (−3.2 kg) accelerated hip BMD loss (−0.81%/y vs −0.42%/y control, P<0.015); losing ≥8% weight more than tripled spine BMD loss, but activity increases ≥4180 kJ/week attenuated spine (not hip) bone loss (Weight loss increases BMD loss). In older adults, the priority reverses: preventing age-related muscle loss (sarcopenia) via adequate protein, resistance activity, and early detection of unintentional weight loss dominates (Sarcopenia prevention priority). Actionable synthesis: pair any weight-loss effort with resistance exercise and adequate protein.

4. Minimum Viable Dose & Honest Caveats

The floor for metabolic health benefit is ~150 min/week moderate activity (30 min, 5 days/week) (150 min/week health floor). Known blind spots: reliance on self-reported activity, insufficient RCT evidence that activity alone prevents weight regain (Weight-regain evidence gap), heterogeneous review populations, industry advisory ties in some PA literature (Disclosed industry COIs), and surrogate outcomes (weight, BMD) rather than hard endpoints (mortality, cardiovascular events). What would change these conclusions: adequately powered trials showing lower activity doses achieve equal maintenance, or new weight-regain RCT evidence contradicting the dose–response.